Chemical.AI announces nearly $14 million Series B funding
"AI and automation plays more and more important role in the chemistry filed"
Computer-generated image
This round will be used to drive the development of Chemical.AI’s ChemFamily products including ChemAIRS, ChemAIOS, ChemAIoT and ChemAILab, based on its proprietary retrosynthesis algorithm as a standard digitalized closed data loop to enhance chemical synthesis efficiency. Chemical.AI’s services facilitate chemists’ research work to be more efficient, more effective in cost/time management and to speed up drug discovery process.
Chemical.AI, an AI-empowered retrosynthesis technology company, leverages artificial intelligence technology and big data to develop tools that can greatly improve the efficiency of R&D research work, and is committed to building an intelligent synthesis management platform to deliver compounds as to shape the future of chemistry. In 2021, Chemical.AI has established an automated synthesis laboratory (ChemAILab) in Shanghai to provide more professional and efficient chemical synthesis services with AI, IoT enhanced tools, together with robotics, to enhance synthesis efficiency to 1.5 – 2 times.
Xuan Yan, Investment Director at Changjiang Securities Innovation said “Automated chemical synthesis has been difficult yet crucial in the industry. It is an inevitable trend for the future to transform. With a group of outstanding experts from chemistry, computer science, automation and artificial intelligence, Chemical.AI has built an intelligent high-throughput chemical synthesis platform based on a cutting-edge retro-synthesis algorithm in the automated synthesis laboratory, which fully integrates dry lab and wet lab solutions. The company has been recognized by world well known customers for its technology capability and superior services during collaboration. We are delighted to be partnering with Chemical.AI on the journey to become the world's leading intelligent chemical synthesis company.”
Sitong You, Partner at Peakvest said “We have been paying attention to AI applications in the pharmaceutical and healthcare fields. We believe that Chemical.AI has become a leader in AI in chemical synthesis field and we highly recognize Dr. Ning Xia, CEO of Chemical.AI, his efforts leading the team along the way. Peakvest will continue to support the company's development and make an impact in the industry together with more customers to join together.”
Dr. Ning Xia, Founder & CEO of Chemical.AI, concluded, “AI and automation plays more and more important role in the chemistry filed. As a company specializing in those fields, Chemical.AI continues to enhance algorithm, integrating data and automation to build an intelligent chemical synthesis platform to facilitate pharmaceutical and chemical materials industries. This round of funding will be utilized to improve ongoing development and expand to global markets. Together with our investors, the new era of intelligent chemistry is coming soon.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the chemical industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.